Gubra stock
Price history
−46.98% over the period1 year: from kr 499.80 (November 20, 2025) to kr 265.00 (November 20, 2026), −46.98%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 265.00 |
| October 30, 2026 | kr 297.80 |
| September 30, 2026 | kr 320.00 |
| August 31, 2026 | kr 379.40 |
| July 31, 2026 | kr 386.80 |
| June 30, 2026 | kr 321.80 |
| May 29, 2026 | kr 357.40 |
| April 30, 2026 | kr 317.40 |
| March 31, 2026 | kr 355.00 |
| February 27, 2026 | kr 391.00 |
| January 30, 2026 | kr 452.00 |
| December 30, 2025 | kr 517.50 |
| November 28, 2025 | kr 491.80 |
| November 20, 2025 | kr 499.80 |
At a glance
The company
Disease-agnostic techbio company offering peptide-based drug discovery and preclinical contract research services across metabolic and fibrotic diseases
Latest results
Quarter to September 30, 2026
TickerLandia's take on Gubra
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−52.47% from the 52-week high
Analysts · 3 analysts
Average targetkr 515.00+94.34% vs. price
Buy 2 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: Gubra
Compared with similar companies: very weak momentum and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh71
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 18.3 73 Forward P/E 173.8 97 Price/book 4.75 44 Profitabilitylow22
How much it earns on revenue and capital.
Metric Value Position in group Net margin −67.2% 9 Operating margin −73.1% 14 Gross margin 75.3% 47 ROE −16.1% 16 ROA −5.9% 24 Earnings stabilityaverage49
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 45.4% 46 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 53 Growthlow35
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +136.48% 89 Earnings growth (year over year) −106.26% 17 Revenue growth (year over year) −94.90% 1 Financial strengthhigh64
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.18 44 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.03 36 Interest coverage 316.7 86 Current ratio 11.4 89 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak5
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −46.98% 2 Distance from 200-day average −22.43% 9 Riskvery high94
How much the price swings.
Metric Value Position in group Volatility (60 days) 53.3% 93 Maximum drawdown (12 months) 50.4% 94
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Gubra is pricier than similar companies
Gubra's Forward P/E: 173.8, +232% against the median of a group of 6 similar companies (52.3).
Compared with 6 similar companies
| Metric | Gubra | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 173.8 | High | |
| Operating margin | -73.1% | Low | |
| ROE | -16.1% | Low | |
| Debt/equity | 0.18 | Middle | |
| Price/book | 4.75 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Gubra. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 126.35M
Latest quarter · Q2 2026
Net income
-kr 109.96M
Latest quarter · Q2 2026
Quarterly net margin
-87.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 4.97B
- EPS
- -kr 11.10
- Volume
- 36.92K
- Daily trading
- €3.19M
How Gubra is changing
All resultsRevenue grew 72.6% a year on average over the last 5 years
Operating margin rose from −14.8% to 81.5%
Profits turn into cash: free cash flow equal to 101% of net income
Returns
Gubra returns with dividends
kr 1,000 invested in Gubra 3 years ago, on November 20, 2023, would be worth kr 2,231 today: +123.06% in total, +30.65% per year. This is the price return only: dividends are excluded.
| Period | Gubra | kr 1,000 becomes |
|---|---|---|
| 1 month | −13.06% | kr 869 |
| 6 months | −22.24% | kr 778 |
| Year to date | −48.79% | kr 512 |
| 1 year | −46.98% | kr 530 |
| 3 years | +123.06% | kr 2,231 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Gubra: technical analysis
Gubra is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 63.6% below its all-time closing high (kr 728.00, December 18, 2024).
- Trend
- Downward
- RSI (14 sessions)
- 35
- Between 30 and 70
- vs 200-session average
- −22.43%
Active signals
New 52-week low.
since November 18, 2026
Support and resistance
Price areas where Gubra has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 315.74+19.15%7 touches, last on November 9, 2026
- Resistancekr 291.60+10.04%2 touches, last on September 16, 2026
- Resistancekr 281.50+6.23%2 touches, last on November 10, 2026
- Last pricekr 265.00
- No support below: the price is near the lows of the year
Volatility and risk
- Volatility (60 sessions, annualised)
- 53.3%
- Largest fall in the last year
- −50.37%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Gubra and its competitors
Based in Horsholm, Denmark, and founded in 2008, Gubra works in peptide-based drug discovery and preclinical contract research. Its contract research and development services cover metabolic and fibrotic diseases and are offered to pharmaceutical and biotechnology companies in Europe, North America and other international markets. The services include in vivo pharmacology, biomarker assays, bioinformatics, next generation sequencing and histology with artificial intelligence pathology.
- Headquarters
- Horsholm, Denmark
- Employees
- 330
- Founded
- 2008
- Chief executive
- Markus Rohrwild
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| GubraGUBRA | $730.02M | -73.1% | — | −22.24% |
| DBV TechnologiesDBV | $572.52M | -5,577.0% | — | −48.73% |
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
Same industry or related industries, similar size. Compare Gubra with its competitors · Full profile
